Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies

Nature Communications

Volumn 6, Issue , 2015, Pages

  Pritchard, Laura K ^a   Spencer, Daniel I R ^b   Royle, Louise ^b   Bonomelli, Camille ^a   Seabright, Gemma E ^a   Behrens, Anna Janina ^a   Kulp, Daniel W ^c   Menis, Sergey ^c   Krumm, Stefanie A ^d   Dunlop, D Cameron ^a   Crispin, Daniel J ^a   Bowden, Thomas A ^e   Scanlan, Christopher N ^a   Ward, Andrew B ^c   Schief, William R ^c,f   Doores, Katie J ^d   Crispin, Max ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Culham Science Centre   (United Kingdom)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; GLYCAN; GLYCOSYLTRANSFERASE; MANNOSE; MANNOSE OLIGOSACCHARIDE; NEUTRALIZING ANTIBODY; GLYCOPROTEIN GP 120; POLYSACCHARIDE;

ANTIBODY; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS; MONOSACCHARIDE; SUGAR;

AFFINITY CHROMATOGRAPHY; ANTIGEN BINDING; ARTICLE; BIOSYNTHESIS; CLUSTER ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PHENOTYPIC PLASTICITY; POTENTIAL N GLYCOSYLATION SITE; PROTEIN CONFORMATION; PROTEIN GLYCOSYLATION; PROTEIN INTERACTION; PROTEIN PROCESSING; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; GLYCOSYLATION; HEK293 CELL LINE; IMMUNOLOGY; MASS SPECTROMETRY; METABOLISM;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODIES, NEUTRALIZING; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HEK293 CELLS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MANNOSE; MASS SPECTROMETRY; MUTAGENESIS, SITE-DIRECTED; POLYSACCHARIDES;

EID: 84933074280     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8479     Document Type: Article

References (70)

1. Leonard C. K., et al. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265, 10373-10382 (1990
2. Li Y., Luo L., Rasool N. & Kang C. Y. Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding. J. Virol. 67, 584-588 (1993
3. Binley J. M., et al. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J. Virol. 84, 5637-5655 (2010
4. Reitter J. N., Means R. E. & Desrosiers R. C. A role for carbohydrates in immune evasion in AIDS. Nat. Med. 4, 679-684 (1998
5. Zhu X., Borchers C., Bienstock R. J. & Tomer K. B. Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39, 11194-11204 (2000
6. Go E. P., et al. Glycosylation site-specific analysis of HIV envelope proteins (JRFL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes accessibility. J. Proteome Res. 7, 1660-1674 (2008
7. Doores K. J., et al. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc. Natl Acad. Sci. USA 107, 13800-13805 (2010
8. Bonomelli C., et al. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS ONE 6, e23521 (2011
9. Walker L. M., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011
10. Lavine C. L., et al. High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection. J. Virol. 86, 2153-2164 (2012
11. Scharf L., et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 7, 785-795 (2014
12. Huang J., et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515, 138-142 (2014
13. Scanlan C. N., et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of a1-2 mannose residues on the outer face of gp120. J. Virol. 76, 7306-7321 (2002
14. Sanders R. W., et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76, 7293-7305 (2002
15. Calarese D. A., et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300, 2065-2071 (2003
16. Walker L. M., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009
17. Pejchal R., et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334, 1097-1103 (2011
18. McLellan J. S., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336-343 (2011
19. Mouquet H., et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl Acad. Sci. USA 109, E3268-E3277 (2012
20. Kong L., et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 20, 796-803 (2013
21. Julien J.-P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342, 1477-1483 (2013
22. Pancera M., et al. Structural basis for diverse N-glycan recognition by HIV-1- neutralizing V1-V2-directed antibody PG16. Nat. Struct. Mol. Biol. 20, 804-813 (2013
23. Julien J.-P., et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc. Natl Acad. Sci. USA 110, 4351-4356 (2013
24. Blattner C., et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40, 669-680 (2014
25. Falkowska E., et al. Broadly neutralizing HIV antibodies define a glycandependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40, 657-668 (2014
26. Julien J.-P., et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 9, e1003342 (2013
27. Sok D., et al. Promiscuous glycan site recognition by antibodies to the highmannose patch of gp120 broadens neutralization of HIV. Sci. Transl. Med. 6, 236ra63 (2014
28. Sok D., et al. The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog. 9, e1003754 (2013
29. Mascola J. R., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207-210 (2000
30. Hessell A. J., et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5, e1000433 (2009
31. Moldt B., et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl Acad. Sci. USA 109, 18921-18925 (2012
32. Burton D. R., et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 12, 396-407 (2012
33. Wei X., et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003
34. Moore P. L., et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 18, 1688-1692 (2012
35. Cutalo J. M., Deterding L. J. & Tomer K. B. Characterization if glycopeptides from HIV-1 SF2 gp120 by liquid chromatography mass spectrometry. J. Am. Soc. Mass Spectrom. 15, 1545-1555 (2004
36. Go E. P., et al. Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. J. Proteome Res. 8, 4231-4242 (2009
37. Pabst M., Chang M., Stadlmann J. & Altmann F. Glycan profiles of the 27Nglycosylation sites of the HIV envelope protein CN54gp140. Biol. Chem. 393, 719-730 (2012
38. Go E. P., et al. Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins. J. Proteome Res. 12, 1223-1234 (2013
39. West A. P., et al. Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proc. Natl Acad. Sci. USA 110, 10598-10603 (2013
40. Kwong P. D., et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659 (1998
41. Trkola A., et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70, 1100-1108 (1996
42. Murin C. D., et al. Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single particle electron microscopy. J. Virol. 88, 10177-10188 (2014
43. Chuang G.-Y., et al. Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. J. Virol. 87, 10047-10058 (2013
44. Willey R. L., et al. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J. Virol. 62, 139-147 (1988
45. François K. O. & Balzarini J. The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry. J. Biol. Chem. 286, 42900-42910 (2011
46. Wang W., et al. A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Retrovirology 10, 14 (2013
47. Kong L., Wilson I. A. & Kwong P. D. Crystal structure of a fully glycosylated HIV-1 gp120 core reveals a stabilizing role for the glycan at Asn262. Proteins Struct. Funct. Bioinformatics 83, 590-596 (2015
48. Crispin M. D. M., et al. Monoglucosylated glycans in the secreted human complement component C3: implications for protein biosynthesis and structure. FEBS Lett. 566, 270-274 (2004
49. Crispin M., et al. Structural plasticity of the semliki forest virus glycome upon interspecies transmission. J. Proteome Res. 13, 1702-1712 (2014
50. Gala F. a & Morrison S. L. The role of constant region carbohydrate in the assembly and secretion of human IgD and IgA1. J. Biol. Chem. 277, 29005-29011 (2002
51. Balzarini J., et al. Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J. Virol. 80, 8411-8421 (2006
52. Witvrouw M., et al. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. J. Virol. 79, 7777-7784 (2005
53. Hu Q., Mahmood N. & Shattock R. J. High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology 368, 145-154 (2007
54. Alexandre K. B., et al. Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology 402, 187-196 (2010
55. Huang X., Jin W., Griffin G. E., Shattock R. J. & Hu Q. Removal of two highmannose N-linked glycans on gp120 renders human immunodeficiency virus 1 largely resistant to the carbohydrate-binding agent griffithsin. J. Gen. Virol. 92, 2367-2373 (2011
56. Geijtenbeek T. B., et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100, 587-597 (2000
57. Kwon D. S., Gregorio G., Bitton N., Hendrickson W. A. & Littman D. R. DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity 16, 135-144 (2002
58. Hong P. W., et al. Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: implications for structural analyses of gp120-DC-SIGN binding. J. Virol. 76, 12855-12865 (2002
59. Shan M., et al. HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog. 3, e169 (2007
60. Banerjee K., et al. Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology 389, 108-121 (2009
61. Banerjee K., et al. Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice. AIDS Res. Hum. Retroviruses 28, 206-214 (2012
62. Dunlop D. C., et al. Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. Glycobiology 20, 812-823 (2010
63. Ho S. N., Hunt H. D., Horton R. M., Pullen J. K. & Pease L. R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77, 51-59 (1989
64. Neville D. C. A., Dwek R. A. & Butters T. D. Development of a single column method for the separation of lipid- and protein-derived oligosaccharides. J. Proteome Res. 8, 681-687 (2009
65. Huang P.-S., et al. RosettaRemodel: a generalized framework for flexible backbone protein design. PLoS ONE 6, e24109 (2011
66. Pancera M., et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl Acad. Sci. USA 107, 1166-1171 (2010
67. Montefiori D. C. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. Chapter 12, Unit 12.11 (2005
68. Walker L. M., et al. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc. Natl Acad. Sci. USA 108, 20125-20129 (2011
69. Bowden T. A., et al. Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis. J. Am. Chem. Soc. 134, 17554-17563 (2012
70. Harvey D. J., et al. Proposal for a standard system for drawing structural diagrams of N- and O-linked carbohydrates and related compounds. Proteomics 9, 3796-3801 (2009